SpyGlass Pharma is a late-stage biopharmaceutical company developing long-acting, sustained drug-delivery therapies for chronic eye disease. Its lead candidate, the BIM-IOL System, attaches drug-eluting pads to an intraocular lens implanted during routine cataract surgery to deliver bimatoprost for years and lower elevated intraocular pressure in open-angle glaucoma or ocular hypertension. The company is also advancing a non-IOL ring-shaped implant for patients who already have artificial lenses. The approach aims to reduce reliance on daily eye drops by combining glaucoma therapy with a common surgical procedure.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -8.7 | — |
| Q3 2025 | 0 | — | -9.8 | — |
| Q4 2025 | 0 | — | -12.6 | — |
| Q1 2026 | 0 | — | -13.8 | — |
| Q2 2026 | 0 | — | -19.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Corvus Pharmaceuticals, Inc. (CRVS), World Acceptance Corporation (WRLD), Ardelyx, Inc. (ARDX), Service Properties Trust (SVC), Alumis Inc. (ALMS), Kelly Services, Inc. (KELYB)